WuXi Vaccines, a vaccine CDMO and joint venture between WuXi Biologics and Shanghai Hile Bio-technology, has entered into a strategic partnership with an undisclosed global vaccine company and signed a 20-year vaccine manufacturing contract valued at approximately $3 billion under which WuXi Vaccines will build a dedicated facility and supply commercial vaccine products. The company had previously announced the signing of a letter of intent in May 2019.

Under the contract, WuXi Vaccines will build an integrated vaccine-manufacturing facility, including drug-substance manufacturing, drug-product manufacturing, manufacture science and technology labs, as well as quality control labs. The facility will be dedicated to manufacture one of its partner’s vaccine products for the global market. The new facility is expected to be operational in 2022.

In November 2019, WuXi Vaccines announced a $240-million investment to build the new vaccine-manufacturing facility in Ireland. The facility is located within the WuXi Biologics campus adjacent to the biologics drug-substance manufacturing facility, which is scheduled for commercial manufacturing in 2021.

Source: WuXi Vaccines